UBS AM’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $42.5M | Sell |
212,888
-150,696
| -41% | -$29.8M | 0.01% | 657 |
|
|
2025
Q4 | $68.7M | Sell |
363,584
-13,017
| -3% | -$2.5M | 0.01% | 554 |
|
|
2025
Q3 | $66.7M | Sell |
376,601
-15,188
| -4% | -$2.26M | 0.01% | 550 |
|
|
2025
Q2 | $44.5M | Buy |
391,789
+336,462
| +608% | +$36M | 0.01% | 734 |
|
|
2025
Q1 | $5.82M | Buy |
55,327
+4,926
| +10% | +$557K | ﹤0.01% | 1495 |
|
|
2024
Q4 | $5.4M | Buy |
50,401
+10,563
| +27% | +$1.19M | ﹤0.01% | 1565 |
|
|
2024
Q3 | $3.99M | Sell |
39,838
-6,031
| -13% | -$607K | ﹤0.01% | 1692 |
|
|
2024
Q2 | $3.86M | Buy |
45,869
+30,130
| +191% | +$2.4M | ﹤0.01% | 1636 |
|
|
2024
Q1 | $1.15M | Hold |
15,739
| – | – | ﹤0.01% | 1937 |
|
|
2023
Q4 | $1.12M | Hold |
15,739
| – | – | ﹤0.01% | 1963 |
|
|
2023
Q3 | $943K | Sell |
15,739
-2,912
| -16% | -$192K | ﹤0.01% | 1988 |
|
|
2023
Q2 | $1.37M | Hold |
18,651
| – | – | ﹤0.01% | 1857 |
|
|
2023
Q1 | $1.37M | Buy |
18,651
+1,030
| +6% | +$73.2K | ﹤0.01% | 1857 |
|
|
2022
Q4 | $1.18M | Sell |
17,621
-10,625
| -38% | -$691K | ﹤0.01% | 1777 |
|
|
2022
Q3 | $1.52M | Hold |
28,246
| – | – | ﹤0.01% | 1739 |
|
|
2022
Q2 | $1.57M | Sell |
28,246
-6,619
| -19% | -$376K | ﹤0.01% | 1727 |
|
|
2022
Q1 | $2.45M | Buy |
34,865
+2,015
| +6% | +$146K | ﹤0.01% | 1698 |
|
|
2021
Q4 | $3.17M | Sell |
32,850
-1,552
| -5% | -$143K | ﹤0.01% | 1639 |
|
|
2021
Q3 | $2.99M | Sell |
34,402
-864
| -2% | -$66.8K | ﹤0.01% | 1642 |
|
|
2021
Q2 | $2.89M | Buy |
35,266
+6,441
| +22% | +$536K | ﹤0.01% | 1683 |
|
|
2021
Q1 | $2.74M | Buy |
28,825
+882
| +3% | +$83.4K | ﹤0.01% | 1624 |
|
|
2020
Q4 | $1.73M | Sell |
27,943
-113,225
| -80% | -$6.46M | ﹤0.01% | 1741 |
|
|
2020
Q3 | $8.39M | Buy |
141,168
+111,105
| +370% | +$7.58M | ﹤0.01% | 985 |
|
|
2020
Q2 | $2.1M | Buy |
30,063
+13
| +0% | +$824 | ﹤0.01% | 1503 |
|
|
2020
Q1 | $1.36M | Sell |
30,050
-83,585
| -74% | -$4.74M | ﹤0.01% | 1577 |
|
|
2019
Q4 | $7.39M | Sell |
113,635
-5,529
| -5% | -$369K | ﹤0.01% | 1055 |
|
|
2019
Q3 | $7.4M | Buy |
119,164
+608
| +0.5% | +$38.2K | 0.01% | 1060 |
|
|
2019
Q2 | $8.44M | Sell |
118,556
-1,796
| -1% | -$132K | 0.01% | 1007 |
|
|
2019
Q1 | $9.44M | Buy |
120,352
+2,395
| +2% | +$181K | 0.01% | 949 |
|
|
2018
Q4 | $9.99M | Sell |
117,957
-7,156
| -6% | -$763K | 0.01% | 875 |
|
|
2018
Q3 | $21.4M | Sell |
125,113
-43,834
| -26% | -$6.61M | 0.02% | 737 |
|
|
2018
Q2 | $21.8M | Sell |
168,947
-11,599
| -6% | -$1.29M | 0.02% | 746 |
|
|
2018
Q1 | $18.6M | Sell |
180,546
-3,001
| -2% | -$297K | 0.01% | 776 |
|
|
2017
Q4 | $15.7M | Buy |
183,547
+53
| +0% | +$4.59K | 0.01% | 803 |
|
|
2017
Q3 | $15.6M | Sell |
183,494
-1,489
| -0.8% | -$118K | 0.01% | 794 |
|
|
2017
Q2 | $14M | Sell |
184,983
-12,912
| -7% | -$903K | 0.01% | 834 |
|
|
2017
Q1 | $13.1M | Sell |
197,895
-8,200
| -4% | -$539K | 0.01% | 840 |
|
|
2016
Q4 | $13.1M | Sell |
206,095
-13,729
| -6% | -$866K | 0.01% | 804 |
|
|
2016
Q3 | $14M | Sell |
219,824
-4,937
| -2% | -$363K | 0.02% | 802 |
|
|
2016
Q2 | $16.7M | Buy |
224,761
+71,306
| +46% | +$5.29M | 0.02% | 745 |
|
|
2016
Q1 | $10.3M | Sell |
153,455
-11,308
| -7% | -$687K | 0.01% | 841 |
|
|
2015
Q4 | $11.1M | Sell |
164,763
-4,626
| -3% | -$286K | 0.01% | 836 |
|
|
2015
Q3 | $9.05M | Buy |
169,389
+24,428
| +17% | +$1.48M | 0.01% | 891 |
|
|
2015
Q2 | $9.12M | Buy |
144,961
+122,740
| +552% | +$6.7M | 0.01% | 915 |
|
|
2015
Q1 | $1.07M | Buy |
22,221
+242
| +1% | +$9.27K | ﹤0.01% | 1606 |
|
|
2014
Q4 | $729K | Buy |
21,979
+1,166
| +6% | +$37.9K | ﹤0.01% | 1738 |
|
|
2014
Q3 | $610K | Buy |
20,813
+2,492
| +14% | +$82.7K | ﹤0.01% | 1764 |
|
|
2014
Q2 | $712K | Sell |
18,321
-6,489
| -26% | -$263K | ﹤0.01% | 1717 |
|
|
2014
Q1 | $1.04M | Sell |
24,810
-1,061
| -4% | -$44.2K | ﹤0.01% | 1548 |
|
|
2013
Q4 | $849K | Sell |
25,871
-196,649
| -88% | -$6.41M | ﹤0.01% | 1579 |
|
|
2013
Q3 | $6.01M | Sell |
222,520
-1,616,799
| -88% | -$45.5M | 0.01% | 939 |
|
|
2013
Q2 | $42.9M | Buy |
+1,839,319
| New | +$33.1M | 0.06% | 353 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
UBS AM's LGND Position: Q1 2026 in Review
UBS AM reduced its Ligand Pharmaceuticals (LGND) stake by 41% in Q1 2026, selling an estimated $29.8M and leaving 212,888 shares worth $42.5M. The position accounts for 0.01% of the portfolio, ranked #657.
UBS AM first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $68.7M in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- UBS AM held 212,888 shares of Ligand Pharmaceuticals worth $42.5M as of Q1 2026.
- UBS AM sold 150,696 Ligand Pharmaceuticals shares in Q1 2026, an estimated $29.8M.
- Ligand Pharmaceuticals made up 0.01% of UBS AM's portfolio in Q1 2026, its #657 holding.
- UBS AM first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- UBS AM's Ligand Pharmaceuticals position peaked at $68.7M in Q4 2025.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.